Big Opportunity in Liver Treatment for Intercept Pharmaceuticals
April 10, 2017 at 08:00 AM EDT
The firm's key program for treating NASH is well positioned, but the space is becoming increasingly crowded.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.